Find a participating AIRFLOW-3 Clinical Trial site or get the latest news and media updates on Nuvaira.

Locate a Clinic

Find a clinic near you that offers treatment with the dNerva Lung Denervation System as part of the AIRFLOW-3 Clinical Trial.

Treatment Locations in the United States

University of Alabama Lung Health Center
Birmingham, Alabama
Scottsdale, AZ
UC Davis Health
Sacramento, CA
Harbor-UCLA Medical Center
Torrance, CA
Ascension St. Vincent’s
Jacksonville, FL
The University of Chicago Medicine
Chicago, IL
AMITA Health Alexian Brothers Medical Center Elk Grove Village
Elk Grove Village, IL
University of Louisville Health
Louisville, KY
The Ohio State University Wexner Medical Center
Columbus, OH
University of Michigan Health
Ann Arbor, MI
Spectrum Health
Grand Rapids, MI
Beth Israel Lahey Health
Burlington, MA
Washington University Medical Center
St. Louis, MO
North Carolina
Duke University Medical Center
Durham, NC
Pinehurst, NC
Temple Health Lung Center
Philadelphia, PA
University of Pittsburgh Medical Center
Pittsburgh, PA
South Carolina
Medical University of South Carolina
Charleston, SC
Houston Methodist Hospital
Houston, TX
St. David’s Medical Center
Georgetown, TX
Medical College of Wisconsin
Milwaukee, WI

Treatment Locations in Europe

Klinik Floridsdorf
Vienna, Austria
Hopital de la Cavale Blanche
Brest, France
CHU de Grenoble
Grenoble, France
Hopital Arnaud de Villeneuve
Montpellier, France
Hopital Pasteur
Nice, France
Claude-Bernard – Hopital Bichat
Paris, France
CHU de Reims
Reims, France
Nouvel Hopital Civil
Strasbourg, France
Hopital Larrey
Toulouse, France
Thoraxklinik Universitätsklinikum Heidelberg
Heidelberg, Germany
Universitätsklinikum Halle
Halle, Germany
University Medical Center Groningen
Groningen, Netherlands
Amsterdam UMC
Amsterdam, Netherlands
Royal Brompton Hospital
London, United Kingdom

Contact us to get more information on referring patients to the AIRFLOW-3 Clinical Trial. 

News and Media

Jan 25, 2022

200th Treatment Milestone for AIRFLOW-3 COPD Trial

300 Patients Treated Worldwide with dNerva® Targeted Lung Denervation therapy MINNEAPOLIS, January 25, 2022 – Nuvaira, a developer of novel therapeutic strategies…

Aug 11, 2021

Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone

Nuvaira Announces AIRFLOW-3 COPD Pivotal Trial Milestone 100 Randomized Patients; Inspire’s CEO Tim Herbert appointed Chairman of the Board MINNEAPOLIS, August…

Nov 23, 2020

Nuvaira Announces Published Two-Year Results in COPD Patients treated with Targeted Lung Denervation

AIRFLOW-2 two-year data confirm sustained reduction of severe COPD exacerbation risk vs. a control group. MINNEAPOLIS, Nov. 23, 2020 /PRNewswire/ — Nuvaira, a…

Jun 08, 2020

Nuvaira Announces FDA Breakthrough Designation for AIRFLOW-3 Pivotal Trial Device

Inspire Medical Systems CEO Tim Herbert has joined Nuvaira Board of Directors MINNEAPOLIS, June 8, 2020 – Nuvaira, a developer of novel therapeutic strategies…

Feb 04, 2020

Nuvaira Announces Chief Financial Officer and Pivotal Study Milestone

Seasoned Veteran Tom Griffin Joins Nuvaira’s Executive Team MINNEAPOLIS, Feb. 4, 2020 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive…

Aug 19, 2019

Nuvaira Announces Peer-Reviewed Publications of Targeted Lung Denervation Mechanisms of Action and Clinical Outcomes

AIRFLOW-2 randomized, sham-controlled one-year data accepted by AJRCCM MINNEAPOLIS, Aug 19, 2019 – Nuvaira, a developer of novel therapeutic strategies to…

Discover if your patient may be a good fit for the AIRFLOW-3 clinical trial